Myeloid hemopathy

Summary

Myeloid hemopathy (MONDO:0015756) is a disease. A subtype of hematopoietic and lymphoid system neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	myeloid hemopathy
Mondo ID	MONDO:0015756
Orphanet	171895
UMLS	C5680514
MedGen	1842523
GARD	0020130
Is cancer (heuristic)	no

Disease family

This is a subtype of hematopoietic and lymphoid system neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › myeloid hemopathy

Related subtypes (8): cavernous hemangioma, thymus neoplasm, bone marrow neoplasm, STAT3-related early-onset multisystem autoimmune disease, lymphoid hemopathy, lymph node neoplasm, spleen neoplasm, hematopoietic and lymphoid cell neoplasm

Subtypes (4): myeloid/lymphoid neoplasms associated with eosinophilia and abnormality of PDGFRA, PDGFRB, FGFR1 or JAK2, myelodysplastic syndrome, myeloproliferative neoplasm, myelodysplastic/myeloproliferative disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.